|
|
Back Issues
|
|
|
|
|
|
ACS Members can sign up to receive C&EN e-mail newsletter.

|
|
|
|
|
|
|

June 3, 2002
Volume 80, Number 22
CENEAR 80 22 pp. 22-26
ISSN 0009-2347
|
|
|
SERONO AT A GLANCE |
Headquarters: Geneva, Switzerland |
Sales: $1.3 billiona |
R&D expenditures: $309 million |
Net income: $317 million |
Employees: 4,600 |
Major products: Gonal-F (follitropin alfa) for infertility ($410 million); Rebif (interferon-beta 1a) for relapsing remitting multiple sclerosis ($380 million); Serostim and Saizen (somatropin) for treatment of HIV-associated wasting and growth retardation, respectively ($233 million total). 82% of all products are made by recombinant technology. |
Website: http://www.serono.com |
a Financial data are for 2001. |
|
|
Page: 1 | 2 | 3 | Previous Page
|
|
Chemical & Engineering News
Copyright © 2002 American Chemical Society |
|
|
|
|
|